Cognitive Functioning in Adults With Somatic Diseases and General Population From a Biopsychosocial Perspective
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBartosz M. Radtke
About this trial
The goal of this observational study is to investigate cognitive functioning profiles in adults with neurologically recognized aphasic syndromes and general population.
The study group consist of minimal 600 adults (over 18 y.o.) who will be examined by qualified diagnosticians. Participants will be evaluated with tasks related to the studied variables: memory, learning and language. Furthermore informations regarding past and present health condition will be collected from participants.
The main questions it aims to answer are:
1. What is the profile of memory and learning among polish adults? 2. Do gender and age moderates patterns of memory and learning functioning among polish adults? 3. What is a specific pattern of language functioning in adults with neurologically recognized aphasic syndromes? 4. Do gender moderates specific patterns of language functioning in adults with neurologically recognized aphasic syndromes?
Researchers will compare the following groups of adults:
1. general population/control group 2. with neurologically recognized aphasic syndromes 3. seniors (over 60 y.o.)
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age from 18 to 60 y.o.
age above 18 y.o.
neurologically recognized aphasic syndromes
age above 60 y.o.
Disqualifiers
age less then 18 y.o.
neurologically recognized aphasic syndromes
age less then 18 y.o.
no neurologically recognized aphasic syndromes
Trial population
Polish adults.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Psychological assessment
Diagnostic testPsychological assessment of memory, learning and language
Treatment groups
600 Participants
are divided into 3 treatment groupsGroup A: General population/control group1 intervention
Group B: Neurologically recognized aphasic syndromes1 intervention
Group C: Seniors (over 60 y.o)1 intervention
Trial outcomes
Primary outcomes
1
Memory and learning
Test of Memory and Learning (second edition). A standardized test measuring memory functioning and learning abilities. The test includes four basic factors (Verbal Memory, Nonverbal Memory, Complex Memory, and Delayed Recall) and five supplementary factors (Attention/Concentration, Sequential Memory, Free Recall, Associative Recall and Learning). The raw scores obtained in each tested subscale are converted into scores scaled based on age norms, ranging from 1 to 20, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.
Time frame
July 3, 2023 until June 30, 20262
Language
Boston Diagnostic Aphasia Examination-Third Edition. A spectrum of tools that helps to identify and distinguish among disorders of language function and neurologically recognized aphasic syndromes. The test have five functional subsections: 1) Conversational and Expository Speech, 2) Auditory Comprehension, 3) Oral Expression, 4) Reading and 5) Writing. The raw scores obtained in each tested subscale are converted into a percentile scale, ranging from 1 to 100, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.
Time frame
July 3, 2023 until June 30, 20263
Socio-demographic data
Author's survey of socio-demographic data, including: gender, month and year of birth, region of residence
Time frame
July 3, 2023 until June 30, 2026Secondary outcomes
1
General mental state
Mini-Mental State Examination. A clinical scale used to examine disorders in a patient's cognitive functioning. The questionnaire consists a series of questions allowing the assessment of the following functions: 1) orientation in time and place, 2) attention/concentration, 3) short-term memory (recall), 4) language skills, 5) visual-spatial abilities, 6) ability to understand and follow the instructions. The maximum score that can be obtained on the test is 30 points. 27-30 is a correct result; 24-26 is a cognitive impairment without dementia; 19-23 mean mild dementia; 11-18 is a moderate degree dementia and 0-10 mean profound dementia.
Time frame
July 3, 2023 until June 30, 20262
Health related data
Author's survey of health related data, including: hearing, eyesight, hypertension, atherosclerosis, previous heart attack, diabetes, endocrine diseases, respiratory system diseases, musculoskeletal system diseases, nervous system diseases, kidney diseases, sleep disorders, hospitalizations, procedures under general anesthesia, cancer, medications.
Time frame
July 3, 2023 until June 30, 20263
Education data
Author's survey of education, including: years of education, level of education, occupation, level of education of the participant's parents.
Time frame
July 3, 2023 until June 30, 2026Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Bartosz M. Radtke
Lead sponsor
Laboratory of Psychological and Educational Tests
Sponsor institution
Source ClinicalTrials.gov